SKYRIZI (Risankizumab) Drug Insight

“SKYRIZI (Risankizumab) Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about SKYRIZI (Risankizumab) for Crohn’s disease (CD) in the 7MM. A detailed picture of the SKYRIZI (Risankizumab) for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the SKYRIZI (Risankizumab) for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SKYRIZI (Risankizumab) market forecast, analysis for Crohn’s Disease Market (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim. Risankizumab is a humanized monoclonal antibody that targets the p19 subunit of IL-23, which subsequently inhibits the binding of IL-23R and activation of the proinflammatory JAK/STAT intracellular signaling pathway. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including Crohn’s disease.

It is approved by the US Food and Drug Administration for the treatment of Crohn's disease. The approved dose to treat adults with moderately to severely active Crohn's disease is 600 mg administered by intravenous infusion over at least one hour at weeks 0, 4, and 8, followed by 360 mg administered by subcutaneous injection at week 12 and every 8 weeks thereafter.

Unlock the Future of Your Industry: Download Our Latest Market Research Report Today! @ Ulcerative Colitis Drugs Market

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the SKYRIZI (Risankizumab) description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).
•  Elaborated details on SKYRIZI (Risankizumab) regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the SKYRIZI (Risankizumab) research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around SKYRIZI (Risankizumab).
•  The report contains forecasted sales of SKYRIZI (Risankizumab) for Crohn’s disease (CD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).
•  The report also features the SWOT analysis with analyst views for SKYRIZI (Risankizumab) in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SKYRIZI (Risankizumab) Analytical Perspective by DelveInsight

• In-depth SKYRIZI (Risankizumab) Market Assessment

This report provides a detailed market assessment of SKYRIZI (Risankizumab) in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• SKYRIZI (Risankizumab) Clinical Assessment

The report provides the clinical trials information of SKYRIZI (Risankizumab) in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Stay ahead with updates on our promising Ulcerative Colitis Therapies. Dive into our pipeline progress now @ Drugs for Ulcerative Colitis

Report Highlights 

•  In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKYRIZI (Risankizumab) dominance.
•  Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to SKYRIZI (Risankizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKYRIZI (Risankizumab) in Crohn’s disease (CD).
•  Our in-depth analysis of the forecasted sales data of SKYRIZI (Risankizumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SKYRIZI (Risankizumab) in Crohn’s disease (CD).

Key Questions

•  What is the product type, route of administration and mechanism of action of SKYRIZI (Risankizumab)?
•  What is the clinical trial status of the study related to SKYRIZI (Risankizumab) in Crohn’s disease (CD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKYRIZI (Risankizumab) development?
•  What are the key designations that have been granted to SKYRIZI (Risankizumab) for Crohn’s disease (CD)?
•  What is the forecasted market scenario of SKYRIZI (Risankizumab) for Crohn’s disease (CD)?
•  What are the forecasted sales of SKYRIZI (Risankizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to SKYRIZI (Risankizumab) for Crohn’s disease (CD)?

 Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?

Also, Read @ Latest DelveInsight Blogs